Analysis of blood, pathology, and clinical data to classify low- and high-risk groups AIDOT (CEO Jaehoon Jung) will unveil its AI-based thyroid cancer recurrence prediction solution, ‘TROC dot AI,’ at the International Hospital and Health Tech Fair (K-HOSPITAL+HEALTHTECH FAIR·KHF 2024), which will be held at COEX, Seoul, from October 2 to 4. TROC dot AI is a patient-tailored in vitro diagnostic medical device software jointly developed by AIDOT and Chungbuk National University Hospital through the "AI Precision Medical Solution Doctor Answer 2.0" project, organized by the Ministry of Science and ICT and the National IT Industry Promotion Agency. This solution analyzes the blood tests, pathology results, and clinical data of patients who have undergone surgery for papillary thyroid cancer, providing a binary classification (low-risk/high-risk) of recurrence probability within one year of the most recent test date. It also quantifies the recurrence risk rate. This is expected to greatly aid in improving prognosis management for thyroid cancer patients by enabling recurrence risk reduction and medication adjustments. CEO Jaehoon Jung stated, "TROC dot AI calculates recurrence rates from blood test results conducted every six months after surgery, allowing trend analysis of recurrence probability compared to past results." He added, "Effective management of thyroid cancer recurrence can contribute to reducing mortality due to cancer recurrence." Beyond TROC dot AI, AIDOT was recently selected for a global innovation zone project and is accelerating its overseas expansion with solutions like ‘COLON dot AI,’ a colonoscopy diagnostic support AI solution being localized and validated in the US, among various other AI medical solutions. 

Raportian / 2024.09.28 / Reporter Hee-seok Jeong